Cannabis
Our work in Cannabis
-
Patient Preference for Medical Cannabis Products in the Absence of Clinical Guidelines
New analysis of New York data finds considerable variability in patient product choice, even for patients with the same condition.
Categorized in -
Spatial and Temporal Trends in the Diagnosis of Opioid-Related Problems in Commercially-Insured Adolescents and Young Adults
USC researchers looked at claims data from privately insured individuals with an opioid-related problem.
Categorized in -
Cannabis Regulations Inadequate Given Rising Health Risks of High-Potency Products
A new USC Schaeffer Center white paper shows how state-level cannabis regulations have weak public health parameters compared to other countries, leaving consumers vulnerable.
Categorized in -
Federal Regulations of Cannabis for Public Health in the United States
State-level cannabis regulations have weak public health parameters compared to other countries, leaving consumers vulnerable.
Categorized in -
Rating the Comparative Efficacy of State-Level Cannabis Policies on Recreational Cannabis Markets in the United States
Schaeffer experts identified identified key cannabis policies and their provisions enacted by U.S. states; rated their theoretical efficacy in a restrictive form for reducing problematic use and impaired driving in the context of a recreational cannabis market as judged by experts; and rated the strength of evidence for each policy.
Categorized in -
Comparison of Medical Cannabis Use Reported on a Confidential Survey vs Documented in the Electronic Health Record Among Primary Care Patients
Schaeffer experts estimate the primary care prevalence of medical cannabis use according to confidential patient survey and to compare the prevalence of medical cannabis use documented in the EHR with patient report.
Categorized in -
Trends in the Use of Cannabis Products in Canada and the USA, 2018 – 2020: Findings From the International Cannabis Policy Study
There is little information on consumption patterns across the diverse range of cannabis product types. This paper examines trends in consumption patterns in Canada and the United States (US) between 2018-2020.
Categorized in -
Impact of Cannabis Legalization on Healthcare Utilization for Psychosis and Schizophrenia in Colorado
Using administrative data from Colorado Hospital Association (CHA) on county-level quarterly ED visits between January 1, 2013, and December 31, 2018, Schaeffer experts applied a difference-in-difference analysis to examine how new exposure to recreational cannabis dispensaries after 2014 differentially influenced the rate of ED visits for psychosis and schizophrenia, comparing counties with no prior medical cannabis dispensary exposure to counties with low or high medical dispensary exposure.
Categorized in -
Schaeffer Expert Warns of Lax Regulation of U.S. Cannabis Market at U.N. Event
Rosalie Liccardo Pacula presented findings at the U.N. Commission on Narcotic Drugs side event.
Categorized in -
Cannabis Legalization and Cannabis-Involved Pregnancy Hospitalizations in Colorado
The primary objective of this study was to evaluate the association between presence of recreational cannabis dispensaries and prevalence of cannabis-involved pregnancy hospitalizations in Colorado.
Categorized in